News
Author: admin als-handoff
-
Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) in Addiction
Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline. SEATTLE, Wash and VANCOUVER, British Columbia, March 25, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline…
-
Achieve Life Sciences to Participate in M-Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer Products. SEATTLE, Wash. and VANCOUVER, British Columbia, March 16, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich,…
-
Achieve Life Sciences Announces Appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Board of Directors
SEATTLE, Wash. and VANCOUVER, British Columbia, March 15, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to the company’s Board of Directors,…
-
Achieve Life Sciences Announces Appointment of Dr. Vaughn Himes to Board of Directors
SEATTLE, Wash. and VANCOUVER, British Columbia, March 14, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Vaughn Himes to the company’s Board of Directors, effective immediately. “We are…
-
Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update
SEATTLE, Wash and VANCOUVER, British Columbia, March 11, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2020 financial results and provided an update on the cytisinicline clinical development program. Recent…